Within group analysis of changes in baseline versus first, second follow-up and the study end scores showed a highly significant reduction in both the groups ( P values included in table), denoting that there was a clinically significant improvement in the signs and symptoms of the acute exacerbation episode of the disease.
← all excerpts
Clinical effectiveness and safety of gemifloxacin versus cefpodoxime in acute exacerbation of chronic bronchitis: A randomized, controlled trial.
1
—
—